HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its price objective trimmed by HC Wainwright from $21.00 to $13.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

PDS Biotechnology Trading Up 0.8 %

Shares of PDS Biotechnology stock opened at $1.25 on Thursday. The company’s fifty day moving average price is $1.41 and its two-hundred day moving average price is $2.17. The firm has a market capitalization of $47.74 million, a PE ratio of -1.08 and a beta of 1.68. PDS Biotechnology has a 52-week low of $1.13 and a 52-week high of $4.56. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. On average, analysts expect that PDS Biotechnology will post -1.2 EPS for the current year.

Institutional Trading of PDS Biotechnology

Several institutional investors have recently bought and sold shares of PDSB. Raymond James Financial Inc. acquired a new position in PDS Biotechnology during the fourth quarter worth $26,000. Jane Street Group LLC bought a new stake in shares of PDS Biotechnology in the 4th quarter worth about $58,000. Marshall Wace LLP increased its position in shares of PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after purchasing an additional 10,837 shares in the last quarter. Virtu Financial LLC bought a new position in PDS Biotechnology during the 4th quarter valued at about $89,000. Finally, Two Sigma Investments LP boosted its position in PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after buying an additional 48,132 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.